Criss SD, Bastani M, ten Haaf K, et al. - Using shared inputs for smoking behavior, costs, and quality of life, researchers independently developed four microsimulation models to assess the health and cost outcomes of annual lung cancer screening with low-dose CT (LDCT). Specifically, they contrasted the cost-efficiency of various stopping ages for lung cancer screening. Current, former, and never-smokers aged 45 years from the 1960 US birth cohort were included in this analysis. Cost-efficiency programs were designated by all three sets of lung cancer screening criteria. Irrespective of underlying uncertainty, the National Lung Screening Trial and Centers for Medicare & Medicaid Services screening approaches demonstrated high likelihoods of cost-efficiency.